Form 4: AN2 Therapeutics Executive Stephen David Prior Reports Stock and Option Awards
SEC Form 4 Filing
Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, reports the acquisition of restricted stock units and stock options.
Summary
- Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, filed a Form 4.
- The filing reports the acquisition of 28,000 shares of common stock in the form of restricted stock units (RSUs) and options to purchase 56,000 shares of common stock on February 26, 2025.
- The RSUs vest 1/4th annually over four years from January 1, 2025.
- The options vest 1/48th monthly over four years from January 1, 2025.
- Prior also holds 61,313 shares of common stock following the reported transactions.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock and option awards, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of the US market and are required by the SEC to provide transparency into the transactions of company insiders.
Stakeholder Impact
- The granting of stock options and RSUs aligns management's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 2024-11-04 | 1/4th of 10,125 RSUs vest annually over four years from this date. |
| 2025-01-01 | Vesting start date for 1/4th of 28,000 RSUs annually over four years and 1/48th of 56,000 stock options monthly over four years. |
| 2025-02-26 | Date of transaction: Acquisition of RSUs and stock options. |
| 2025-02-28 | Date of Form 4 filing. |
| 2026-01-01 | Vesting date for 12,031 RSUs. |
| 2035-02-25 | Expiration date for stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.